CG Oncology Files Definitive Proxy Statement

Ticker: CGON · Form: DEF 14A · Filed: Apr 25, 2025 · CIK: 1991792

Cg Oncology, Inc. DEF 14A Filing Summary
FieldDetail
CompanyCg Oncology, Inc. (CGON)
Form TypeDEF 14A
Filed DateApr 25, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, annual-meeting, governance

TL;DR

CG Oncology just dropped its proxy statement for the June 5th shareholder meeting. Get ready to vote!

AI Summary

CG Oncology, Inc. filed its definitive proxy statement on April 25, 2025, for its annual meeting of stockholders on June 5, 2025. The filing covers the fiscal year ending December 31, 2024. The company is based in Irvine, California, and operates in the biological products sector.

Why It Matters

This filing provides shareholders with essential information regarding the upcoming annual meeting, including details on voting matters and company performance, enabling informed participation in corporate governance.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEF 14A) that provides information to shareholders and does not inherently introduce new risks.

Key Players & Entities

  • CG Oncology, Inc. (company) — Registrant
  • April 25, 2025 (date) — Filing Date
  • June 5, 2025 (date) — Annual Meeting Date
  • December 31, 2024 (date) — Fiscal Year End
  • Irvine, California (location) — Company Business Address

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with a proxy statement for the annual meeting of stockholders, detailing information necessary for them to vote on matters presented at the meeting.

When is the annual meeting of stockholders for CG Oncology, Inc. scheduled?

The annual meeting of stockholders for CG Oncology, Inc. is scheduled for June 5, 2025.

What fiscal year does this proxy statement cover?

This proxy statement covers the fiscal year ending December 31, 2024.

Where is CG Oncology, Inc. located?

CG Oncology, Inc. is located at 400 Spectrum Center Drive, Suite 2040, Irvine, CA 92618.

What type of company is CG Oncology, Inc. according to its SIC code?

According to its SIC code (2836), CG Oncology, Inc. is in the Biological Products (No Diagnostic Substances) industry.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 25, 2025 regarding CG Oncology, Inc. (CGON).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.